VYVGART Hytrulo

Product NDC
73475-3102
11-digit product format
734753102
Labeler code
73475
Product ID
73475-3102_63be80ae-0be8-4da6-9c97-6c5c98ac9043
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
efgartigimod alfa and hyaluronidase (human recombinant)
Dosage form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Labeler
argenx US
Application
BLA761304
Marketing category
BLA
Marketing start
2023-06-20
Substance
EFGARTIGIMOD ALFA; HYALURONIDASE (HUMAN RECOMBINANT)
Active strength
180; 2000 mg/mL; U/mL
Pharmacologic classes
Endoglycosidase [EPC], Glycoside Hydrolases [CS], Neonatal Fc Receptor Blocker [EPC], Neonatal Fc Receptor Blockers [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Additional Listing Data#

Finished product
Yes
Brand name base
VYVGART Hytrulo
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
EFGARTIGIMOD ALFA180 mg/mL
HYALURONIDASE (HUMAN RECOMBINANT)2000 U/mL

Harmonized Identifiers#

Field, Values table
FieldValues
Unii743QUY4VD8, 961YV2O515
Rxcui2639951, 2639957, 2712083, 2712088

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fba5a780-b52d-4964-b662-1526b044aec4Product name120260127
64196b0b-840e-435b-8afa-0b0e9d9cea99Product name120251024
4b151d8d-9b47-43df-bccb-6abc1c4e7194Product name120250331
d745a796-f789-46a3-afa3-79dead22a863Product name120250331
00bb4496-246c-4f2c-910a-2b2783035958Product name120231025
e0c39752-98ba-4b96-a1e0-1fe4c0365ed0Product name120220720
bd11614e-4776-4a92-aaca-2bcbb5f710edProduct name120210115
0c6eff6a-9a1e-468b-b9ca-6bc864c2e8cbProduct name120200925
6d78c268-2e9d-bd45-9f2d-965fd0e582caProduct name220200323
b914e981-d6dc-4748-bd51-accd6b85b817Product name120190618
4597a7a9-59c8-4eb4-b516-4f26fa3dfe4bProduct name120170804
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
1681bc73-b05f-12c3-1075-382ae39f449cProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
73475-3102-32024-01-30C16284748780-11030e365-4ba8-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
73475-3102-3VYVGART Hytrulo1 in 1 CARTONINJECTION, SOLUTION112
73475-3102-3VYVGART Hytrulo5.6 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION5.612

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
73475-3102-3ML - Milliliter73475-3102f0e0fbea-e904-4a87-b610-8ef15d5a136b12023-07-06

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
73475-3102VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)) INJECTION, SOLUTION [ARGENX US]7Current NDC, 2 package rows20250418_7104d9e5-9910-47f5-9a93-741ac50f43b6.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2712083efgartigimod alfa 1,000 MG / hyaluronidase-qvfc 10,000 UNT in 5 ML Prefilled SyringePSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT in 5.6 ML InjectionPSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2712088VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled SyringePSN7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957VYVGART Hytrulo 1008 MG / 11,200 UNT in 5.6 ML InjectionPSN7104d9e5-9910-47f5-9a93-741ac50f43b612
27120885 ML efgartigimod alfa-qvfc 200 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Prefilled Syringe [Vyvgart Hytrulo]SBD7104d9e5-9910-47f5-9a93-741ac50f43b612
26399575.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection [Vyvgart Hytrulo]SBD7104d9e5-9910-47f5-9a93-741ac50f43b612
27120835 ML efgartigimod alfa-qvfc 200 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Prefilled SyringeSCD7104d9e5-9910-47f5-9a93-741ac50f43b612
26399515.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML InjectionSCD7104d9e5-9910-47f5-9a93-741ac50f43b612
2712083efgartigimod alfa 1,000 MG / hyaluronidase-qvfc 10,000 UNT per 5 ML Prefilled SyringeSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639951efgartigimod alfa-qvfc 1008 MG / hyaluronidase-qvfc 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2712088Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1,000 MG / 10,000 UNT) per 5 ML Prefilled SyringeSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT) per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612
2639957Vyvgart Hytrulo 1008 MG / 11,200 UNT per 5.6 ML InjectionSY7104d9e5-9910-47f5-9a93-741ac50f43b612

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
73475-3102-3734753102031 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in 1 VIAL, SINGLE-DOSE2023-06-20NoNoCurrent